Insights & Analysis
Curated perspectives on AI, real-world evidence, healthcare data science, and industry trends.
Every Wednesday: a concise take on real-world evidence, AI, or data science leadership. No fluff.
Featured Insights
Curated articles and analysis
The Rise of Foundation Models in Healthcare
How large-scale AI models are beginning to reshape clinical decision support, drug discovery, and evidence generation. From GPT-based clinical text analysis to multimodal models combining imaging and genomic data, foundation models promise to accelerate every stage of the evidence lifecycle.
Practical Applications of LLMs for Clinical Text
Exploring real-world use cases for large language models in extracting structured data from unstructured clinical notes, discharge summaries, and pathology reports. Key considerations include hallucination mitigation, validation frameworks, and regulatory implications for AI-generated clinical insights.
FDA's Evolving Stance on Real-World Evidence
A look at recent FDA guidance documents and how the regulatory environment for real-world evidence continues to mature for drug development and post-market surveillance. The 2025 framework updates signal growing acceptance of RWE for label expansion and safety monitoring decisions.
Best Practices for EHR-Based Studies
Key methodological considerations for designing rigorous observational studies using electronic health record data, from data quality assessment and phenotype validation to confounding control strategies and sensitivity analyses that strengthen causal claims.
2026 Trends in Healthcare Data Science
The top trends shaping healthcare analytics this year, from federated learning and synthetic data generation to the growing role of AI in health technology assessment. How organizations are building data science capabilities to meet evolving evidence demands.
Building High-Performance Analytics Teams
Lessons learned from scaling data science teams in healthcare organizations, including hiring strategies for blending clinical domain expertise with technical skills, structured mentorship programs, and building a culture of scientific rigor alongside business impact.
From the Wire
Latest news from across the healthcare data science landscape
Does the world need ‘guy-necologists’?
And other health news from the Morning Rounds newsletter
STAT+: Hims to buy Eucalyptus as it looks to expand globally
Hims & Hers is buying the Australian telehealth firm Eucalyptus as it looks to make inroads in more countries globally.
STAT+: What to expect from Gossamer Bio’s late-stage lung disease study
Gossamer Bio will be reporting the outcome of a late-stage study in pulmonary arterial hypertension. Here's what to know.
STAT+: 5 key people to watch at HHS after Trump’s shake-up
HHS has elevated a new team of health policy experts, including a former health IT exec and a Trump administration veteran.
Opinion: My biggest GLP-1 ethical problem: patients who don’t want to stop
Some GLP-1 patients are begging to stay on the drugs just a little bit longer, presenting an ethical dilemma for doctors.
FDA Approves Labeling Changes to Menopausal Hormone Therapy Products
The U.S. Food and Drug Administration has approved drug labeling changes to six menopausal hormone therapy products, also known as hormone replacement therapy (HRT), to clarify risk considerations for
FDA Approves First-of-Its-Kind Device to Treat Pancreatic Cancer
The U.S. Food and Drug Administration has approved a first-of-its-kind device for the treatment of adult patients with locally advanced pancreatic cancer.
FDA Launches Assessment of BHA, a Common Food Chemical Preservative
The U.S. Food and Drug Administration today launched a comprehensive re-assessment of butylated hydroxyanisole (BHA), a chemical preservative used in food.
FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs
Today, the U.S. Food and Drug Administration is announcing its intent to take decisive steps to restrict GLP-1 active pharmaceutical ingredients (APIs) intended for use in non-FDA-approved compounded
FDA Takes New Approach to "No Artificial Colors" Claims
Today, the U.S. Food and Drug Administration took additional steps to support the transition of our nation’s food supply from the use of artificial petroleum-based colors to alternatives derived from
Health Affairs Web First: Choosing Wisely Campaign
In 2012, the American Board of Internal Medicine (ABIM) Foundation, in partnership with Consumer Reports, founded the Choosing Wisely® campaign, to raise awareness among physicians and patients about
The Transformation Of Medical Education From Choosing More To Choosing Wisely
Clinicians and patients value thoroughness. However, as new testing and treatment options have multiplied over the past few decades, the desire to leave no stone unturned has had unintended consequenc
Stay Connected
Follow along for the latest insights on AI, real-world evidence, and healthcare data science.